ArticleClinical neuropharmacology
Opicapone Improves the Pharmacokinetics of Levodopa Administered as Extended-Release Capsules.
Article in Clinical neuropharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveBoth a catechol-O-methyltransferase inhibitor and extended-release (ER) levodopa formulations may enhance levodopa treatment through a more continuous levodopa delivery to the striatum; the combination of these therapies has not undergone a pharmacokinetic study. We evaluated the effects of once-daily opicapone 50 mg on levodopa plasma pharmacokinetics when added to a carbidopa/levodopa (CD/LD)-ER formulation (RYTARY®). MATERIALS AND
methodsThis was an exploratory, open-label study of levodopa's pharmacokinetics measured over 24 hours in healthy adults. Enrolled individuals received CD/LD-ER three times daily (TID) alone for 3 days, followed by once-daily opicapone for 14 days. On the last 3 days of the opicapone regimen, participants received CD/LD ER TID again. Pharmacokinetic parameters were evaluated after the 3-day exposure to CD/LD-ER alone and with concomitant administration of opicapone.
resultsEighteen healthy adults (9 male, 9 female) entered and completed the study. Levodopa exposure (area under the time-concentration curve) was higher with opicapone than with CD/LD-ER alone across all dosing intervals, including between 21:00 and 07:00 (10801.5 vs. 5153.3 ng/mL·h). Over 24 hours, mean levodopa trough concentration (Ctrough) was higher with opicapone versus CD/LD-ER alone (677.2 vs. 266.8 ng/mL), as was minimum Ctrough (302.9 vs. 41.3 ng/mL). There was a greater increase in Ctrough (208%) than in maximum plasma concentration (75%), decreasing the fluctuation index by 38%.
conclusionsAdding opicapone to CD/LD-ER enhanced levodopa pharmacokinetics in healthy adults, by increasing levodopa trough levels. Notably, opicapone increased overnight and morning levodopa concentrations and decreased daily levodopa concentrations, sub-therapeutic for Parkinson disease patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.